CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

about

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

Item

http://www.wikidata.org/entity/Q52714322

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

@en

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

@nl

type

Item

label

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

@en

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

@nl

prefLabel

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

@en

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

@nl

P1476

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells

@en

P2093

A Bondanza

http://www.w3.org/2001/XMLSchema#string

A Pisacane

http://www.w3.org/2001/XMLSchema#string

G M Casucci

http://www.w3.org/2001/XMLSchema#string

L D Ambrosio

http://www.w3.org/2001/XMLSchema#string

L Gammaitoni

http://www.w3.org/2001/XMLSchema#string

R Rotolo

http://www.w3.org/2001/XMLSchema#string

U Rossotti

http://www.w3.org/2001/XMLSchema#string

P2860

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor

Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.

5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.

P304

e1423167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2017.1423167

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29721373

http://www.w3.org/2001/XMLSchema#string

P932

5927525

http://www.w3.org/2001/XMLSchema#string